MDaaS Global

A diagnostics company that decided it was also a software company

There is a version of MDaaS Global that is easy to describe and slightly boring: a Nigerian company that runs medical diagnostic clinics. X-rays, ultrasounds, ECGs, blood chemistry. The sort of thing that exists in every functioning health system and that people only think about when they need it, which is usually at a bad moment. This is a real and accurate description of MDaaS, and it undersells the company by roughly the same margin that "a company that ships boxes" undersells a logistics giant.

The more interesting description is that MDaaS looked at the problem of getting a chest x-ray to a person in an underserved Nigerian community and concluded that the hard part was not the x-ray machine. The hard part was everything around it - the referral, the result, the payment, the follow-up, the fact that the specialist who reads the scan is three states away. So the company did the thing that software people do when they see a coordination problem: it built an operating system. It is called BeaconOS, it launched in 2023, and it treats a network of physical clinics roughly the way a laptop's OS treats its hardware - as components to be connected and optimized rather than buildings to be visited.

That instinct is not an accident. MDaaS was founded in 2017 by a team that includes a software engineer, and it began life under a name that tells you the original thesis: MDaaS, short for Medical Devices as a Service. The first business was importing refurbished diagnostic equipment and making it available to Nigerian hospitals. This is a perfectly good business. The company shut it down anyway.

The pivot nobody asks for

Pivoting from selling equipment to operating your own clinics is the kind of decision that looks obvious in a case study and terrifying in real life. Selling scanners is capital-light and someone else runs the clinic. Operating the clinic means you own the rent, the staff, the machine downtime, the patient who doesn't show up, and the HMO that is slow to pay. MDaaS made the switch anyway, trading as BeaconHealth Diagnostics, because the equipment business had a ceiling: you can sell a hospital a machine, but you cannot make that machine reach a patient who never gets referred there in the first place.

The bet was that owning the whole chain - clinic, software, logistics, payer integration - was the only way to actually move the number that matters, which is how many people get a correct diagnosis in time to do something about it. As of the most recent figures, that number is over 275,000 patients since inception, with 108,724 in a single recent year, of whom 60.8% were women. That last statistic is worth sitting with. When you place good diagnostics close to people and price them within reach, the population that shows up shifts - and it skews toward the people traditional systems miss.

The founding, and the father

The origin story is unusually specific. CEO Oluwasoga Oni grew up in a small town in Ondo State, in southwest Nigeria, where his father was a doctor at the town hospital and routinely could not find the right working equipment to run the tests his patients needed. Oni left for the United States, qualified as a software engineer, and then did the thing that quietly reshapes a lot of lives: he went back to school. At MIT, in a systems-design program, he took a class that challenged students to build a business capable of impacting a billion lives. He already knew the problem. He'd grown up inside it.

He did not build it alone. MDaaS's founding team includes Genevieve Barnard Oni, the company's CFO and Oni's wife - the two run the company together, which is its own kind of operational stress test - along with Joseph McCord on supply chain and Opeyemi Ologun as country manager. It is a founding team that maps cleanly onto the business: someone for the money, someone for the machines, someone for the ground game, and someone holding the whole thesis together.

What the money is for

MDaaS has raised about $6.8 million total, which is not a lot by the standards of health-tech headlines and is a great deal by the standard of what it has built with it. The path runs from a $1M seed in 2019, through a $2.3M seed extension in 2021 led by Newtown Partners, to a $3M Pre-Series A in 2024 co-led by Aruwa Capital and Newtown Partners with follow-on from Ventures Platform. Notably, the 2024 round is earmarked less for more buildings and more for more software: an affiliate-clinic portal for real-time referrals and results, deeper HMO integrations to speed up authorizations, and a patient-facing app for booking, results, and insurance.

This is the tell. A pure clinic chain raises money to open clinics. MDaaS is raising money to build the connective tissue between clinics, and between clinics and everyone else - the 1,300-plus referring clinicians, the 1,000-plus partner organizations, the 34 HMOs. The clinics are the visible product. The network is the actual one.

Why any of this is hard, and why it matters

The demand side is not in doubt. Non-communicable diseases - hypertension, diabetes - are rising among African workers, which is exactly why MDaaS built Beam, a tool that lets corporate partners run occupational and preventive screening for their teams. The supply side is where companies break: staffing clinics in ten states, keeping imaging machines running in places with unreliable power, getting paid by insurers, and holding quality steady across a growing footprint. MDaaS's answer is to make the software carry the coordination load that would otherwise crush an operations team. Olewerk, its workflow app, now runs on the floor of every location.

None of this guarantees the company wins. Diagnostics is a grind, expansion is expensive, and the graveyard of African health-tech includes well-funded names. But MDaaS has a coherent theory of the case - own the chain, digitize the coordination, price for access - and a decade of receipts. In 2026, MIT's Africa Business Club made Oni the first recipient of its Alumni Impact Award. Awards are not revenue. But they are a reasonable proxy for the judgment that this particular company, out of that particular MIT class, actually built the billion-lives thing it set out to build.

Clinics on the ground, software in the middle

Four founders, one thesis

$6.8M across three rounds